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Background: MUC1 is a transmembrane mucin that plays an
important role in tumor progression. Many clinical studies have
suggested that the expression pattern of MUC1 core protein can be
a useful prognostic marker in various malignancies, but the prog-
nostic significance in non–small cell lung cancer (NSCLC) remains
uncertain. We performed a study to assess clinical significance,
especially prognostic impact, of MUC1 expression in NSCLC.
Methods: A total of 62 patients with completely resected pathologic
stage I to IIIA NSCLC were retrospectively reviewed. Histologic
sections cut from primary tumors were immunohistochemically
stained with an anti-MUC1 monoclonal antibody (CA15-3, clone
DF3), which recognizes unglycosylated epitope of MUC1 core
protein. According to MUC1 expression pattern, each patient was
classified into the high-grade polarized expression (HP), the low-
grade polarized expression (LP), or the depolarized expression (D)
group.
Results: Twenty-four (38.7%), 21 (33.9%), and 17 (27.4%) patients
were classified into the HP group, the LP group, and the D group,
respectively. HP was exclusively seen in adenocarcinoma, mostly in
well-differentiated adenocarcinoma. D was correlated with progres-
sive stage and lymph node metastasis. Postoperative survival of the
D group seemed to be poorer than that of the HP group for all
NSCLC patients, and the difference was enhanced in adenocarci-
noma patients.
Conclusion: A novel classification of MUC1 expression pattern
(HP, LP, and D) was correlated with tumor differentiation and
postoperative survival in NSCLC, especially in lung adenocarci-
noma.
Key Words: MUC1, Lung cancer, Prognosis, Immunohisto-
chemistry.
(J Thorac Oncol. 2006;1: 46–51)
Primary lung cancer is the leading cause of death fromcancer in most industrialized countries, and non–small
cell lung cancer (NSCLC) accounts for 70% to 80% of
primary lung cancer. Although some improvements in sur-
gery, chemotherapy, and radiotherapy have been made re-
cently, the prognosis of NSCLC patients remains unsatisfac-
tory. The most important reason for the poor prognosis is the
high incidence of nodal and/or distant metastases. To im-
prove the prognosis, it is essential to reveal biological char-
acteristics leading to development of metastasis in NSCLC.
MUC1 is a transmembrane mucin consisting of a
heavily O-glycosylated extracellular domain, a transmem-
brane domain, and a cytoplasmic tail of 72 amino acids; the
extracellular domain has a variable number of highly con-
served tandem repeats of 20 amino acids.1–3 In normal tis-
sues, including bronchial mucosa and type II pneumocytes,
MUC1 is expressed on the apical surface of normal glandular
epithelial cells.4–6 In neoplastic tissues, MUC1 expression
may be up-regulated, or the glycosylation may be altered and
MUC1 may be expressed on the entire cell surface (depolar-
ized expression).4,7 Experimental studies have shown that
MUC1 may reduce cell–cell and cell–matrix adhesion,8,9 and
the cytoplasmic domain of MUC1 interacts with a variety of
molecules involved in tumor proliferation such as epidermal
growth factor receptor, c-Src, -catenin, and Grb2,10–13 and
that MUC1 overexpression is correlated with tumorigenesis
in a mouse model.14 These studies have suggested that MUC1
plays important roles in development and progression of
malignant tumors.
MUC1 is also recognized as a target molecule in
immunotherapy for various malignant tumors, because un-
masked epitopes of MUC1 core protein expressed on tumor
cells can elicit a strong antitumor immunity.15–18 When we
select candidates for MUC1-targeted immunotherapy, it is
important to evaluate MUC1 expression on the surface of
tumor cells.
It has been reported that MUC1 is an important prognostic
factor in various malignant tumors.19–30 These studies have
suggested that alteration in the expression pattern of MUC1 is
important in evaluation of clinical significance of MUC1. In
NSCLC, however, the clinical significance including prognostic
impact of MUC1 expression status remains uncertain.6,31,32
Thus, we conducted a detailed study on MUC1 expression,
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including the cellular distribution of MUC1, in correlation with
clinical outcomes in NSCLC, and reported a significant corre-
lation between a novel classification of MUC1 expression pat-
tern and histologic differentiation and postoperative survival.
PATIENTS AND METHODS
Patients and Tissue Preparation
A total of 63 consecutive patients with pathologic stage
I to IIIA NSCLC, who underwent complete tumor resection
and mediastinal lymph node dissection without any preoper-
ative therapy at the Kyoto University Hospital between July
of 1996 and October of 1998 and from whom written in-
formed consent for the research use of resected tumor tissues
were taken, were retrospectively reviewed (Table 1). Com-
plete tumor resection was considered achieved when micro-
scopic cancer cells were identified neither in the margin of
resection of the tumor nor in the highest mediastinal lymph
nodes.33 One patient was excluded from the study because of
operation-related death, and thus a final total of 62 patients
were evaluated. Pathologic stage was evaluated according to
the current tumor, node, metastasis classification as revised in
1997.34 Histologic type and tumor cell differentiation were
determined using the current classification by the World
Health Organization as revised in 2004.35 For analyses ac-
cording to the differentiation of cancer cells, well-differenti-
ated squamous cell carcinoma and adenocarcinoma were
classified as well-differentiated tumors and moderately dif-
ferentiated squamous cell carcinoma and adenocarcinoma as
moderately differentiated tumors; large-cell carcinoma and
poorly differentiated squamous cell carcinoma and adenocar-
cinoma were classified as poorly differentiated tumors. For
all these patients, records of surgery, inpatient medical
records, chest radiography films, whole-body computed to-
mography films, and bone scanning films were reviewed
without knowledge of the results of the IHS. As postoperative
adjuvant therapy, oral administration of UFT (tegafur and
uracil) was prescribed for patients with pathologic stage I to
IIB, and cisplatin based chemotherapy was prescribed for
patients with pathologic stage IIIA. Follow-up of postopera-
tive clinical course was conducted by outpatient medical
records and by inquiries by telephone or letter.
Histologic specimens were available for immunohisto-
chemical staining (IHS) from all patients. Tumor specimens
were immediately fixed in 10% (v/v) formalin, and then
embedded in paraffin. Serial 4-m sections were prepared
from each primary tumor sample and were served for hema-
toxylin and eosin staining and IHS for evaluation of MUC1
expression. Slides were reviewed independently by two in-
vestigators (S.N. and K.T.) without knowledge of any clinical
data. A different evaluation of MUC1 expression was made
in seven patients (11.3%). The field was reevaluated until the
evaluation coincided. This study was reviewed and approved
by the Ethics Committee of the Graduate School and Faculty
of Medicine, Kyoto University.
TABLE 1. Patient Characteristics and MUC1 Expression in Resected NSCLC
No. of Patients (%) HP (%) LP (%) D (%) p Value
Total 62 (100) 24 (38.7) 21 (33.9) 17 (27.4)
Mean age (yr) 63.5 63.7 66.3 0.643
65 35 (56.5) 12 (34.3) 11 (31.4) 12 (34.3) 0.381
65 27 (43.5) 12 (44.4) 10 (37.0) 5 (18.5)
Gender
Male 41 (66.1) 10 (24.4) 16 (39.0) 15 (36.6) 0.004
Female 21 (33.9) 14 (66.7) 5 (23.8) 2 (9.5)
Histologic type
Adenocarcinoma 47 (75.8) 24 (51.1) 17 (36.2) 6 (12.8) 0.0001*
Squamous cell 11 (17.7) 0 1 (9.1) 10 (90.9)
Large-cell 4 (6.5) 0 3 (75.0) 1 (25.0)
Tumor differentiation
Well 30 (48.4) 21 (70.0) 7 (23.3) 2 (6.7) 0.0001
Moderate/poor 32 (51.6) 3 (9.4) 14 (43.8) 15 (46.9)
Pathologic stage
I 44 (71.7) 22 (50.0) 15 (34.1) 7 (15.9) 0.002
II/IIIA 18 (29.3) 2 (11.1) 6 (33.3) 10 (55.6)
Pathologic T factor
T1 30 (48.4) 16 (53.3) 11 (36.7) 3 (10.0) 0.008
T2/T3 32 (51.6) 8 (25.0) 10 (31.3) 14 (43.8)
Pathologic N factor
N0 47 (75.8) 22 (46.8) 16 (34.0) 9 (19.1) 0.017
N1/N2 15 (24.2) 2 (13.3) 5 (33.3) 8 (53.3)
*Comparison between adenocarcinoma and squamous cell carcinoma plus large-cell carcinoma. HP, high-grade polarized expression; LP, low-grade polarized expression; D,
depolarized expression.
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Immunohistochemical Staining
Expression of MUC1 was evaluated with IHS using a
streptavidin-biotinylated horseradish peroxidase detection
system (LSAB kit/HRP; DAKO, Kyoto, Japan). Sections
were incubated overnight at 4°C with an anti-MUC1 mouse
monoclonal antibody (CA15-3, clone DF3; DAKO) diluted at
1:50 without antigen retrieval; for negative control slides, the
primary antibody was omitted. As a chromogen, diaminoben-
zidine-tetrahydrochloride (0.03%) containing 0.1% hydrogen
peroxide was used, and sections were counterstained with
hematoxylin.
Evaluation of Immunohistochemical Analysis
Staining intensity of MUC1 expression was first clas-
sified into negative or positive, and then, when positive, each
tumor cell was further classified according to the expression
pattern into polarized or depolarized expression as follows:
(1) polarized expression when MUC1 is localized in the cell
membrane of apical portion of tumor cells (Figure 1 A), (2)
depolarized expression when MUC1 is observed over the
entire cell surface or whole cytoplasm (Figure 1 B). Accord-
ing to the percentage of tumor cells showing polarized MUC1
expression and that with depolarized MUC1 expression,
MUC1 expression status of each patient was finally divided
into the high-grade polarized (HP), the low-grade polarized
(LP), or the depolarized (D) group (Table 2). According to
the definition, a patient with tumor showing no MUC1 ex-
pression was classified into the LP group.
Statistical Analysis
Counts were compared by means of the 2. Continuous
data were compared using the Student’s t test if the sample
distribution was normal or using the Mann-Whitney U test if
the sample distribution was asymmetrical. The postoperative
overall survival rate was analyzed by the Kaplan-Meier
method, and the differences in survival rates were assessed by
the log rank test and the generalized Wilcoxon’s test. Multi-
variate analysis of prognostic factors was performed using the
Cox’s regression model. Differences were considered signif-
icant when p  0.05. All statistical manipulations were
performed using the StatView software system for Macintosh
(Version 4.5; Abacus Concepts Inc., Berkeley, CA).
RESULTS
MUC1 Expression and Clinicopathologic
Features
Of all 62 patients, 24 (38.7%), 21 (33.9%), and 17
(27.4%) were classified as the HP, LP, and D group, respec-
tively. Clinicopathologic features according to MUC1 status
are summarized in Table 1. Male patients were less fre-
quently classified into the HP group, and more frequently
were classified into the D group (p  0.004). Well-differen-
tiated tumor and early-stage patients were more frequently
classified into the HP group; moderately to poorly differen-
tiated tumor and advanced-stage patients were more fre-
quently into the D group.
The most significant was the correlation between
MUC1 status and histologic type; most squamous cell carci-
noma patients were classified into the D group, and no
squamous cell carcinoma or large-cell carcinoma patient was
into the HP group. As adenocarcinoma patients were distrib-
uted into the three groups to some degree, an analysis only in
adenocarcinoma patients were further performed (Table 3). A
significant correlation between tumor differentiation and
MUC1 status was observed; no well-differentiated tumor
patient was classified into the D group, and most well-
differentiated tumor patients including two bronchioalveolar
carcinoma patients were classified into the HP group. Be-
cause 17 (89.5%) of the 19 female adenocarcinoma patients
had well-differentiated tumors, the female patients might be
more frequently classified into the HP group. There was no
significant correlation between MUC1 status and age, patho-
logic stage, pathologic T factor, or pathologic N factor.
MUC1 Status and Postoperative Survival
For all patients, 5-year survival rates of the HP, LP, and
D patients were 78.3%, 51.5%, and 56.2%, respectively,
showing a trend of a favorable prognosis in HP patients and
a poor prognosis in D patients (p 0.134 by the log rank test
and p  0.081 by the Wilcoxon test among the three groups)
(Figure 2); the p values between HP and D patients by the log
rank test and the Wilcoxon test were 0.074 and 0.042,
respectively (Figure 2).
FIGURE 1. MUCI expression in NSCLC with immunohistochemical staining. (A) High-grade polarized expression (HP) pattern
of MUC1 expression in a well-differentiated papillary adenocarcinoma case (original magnification, 100). (B) Depolarized (D)
expression pattern of MUC1 in a poorly differentiated adenocarcinoma case (original magnification, 200).
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For adenocarcinoma patients, the difference in the post-
operative survival between the three groups as defined with
MUC1 status was enhanced. The 5-year survival rates of HP,
LP, and D patients were 78.3%, 51.4%, and 40.0%, respec-
tively, showing a significant difference among the three
groups (p  0.039 by the log rank test and p  0.012 by the
Wilcoxon test) (Figure 3); the p values between HP and D
patients by the log rank test and the Wilcoxon test were 0.015
and 0.006, respectively (Figure 3). A multivariate analysis
taking into account age, pathologic T factor, lymph node
metastasis, and MUC1 expression status in adenocarcinoma
patients showed that depolarized MUC1 expression was a
significant and independent factor to predict a poor postop-
erative prognosis (relative risk to high-grade polarized MUC1
expression, 4.73; 95% confidence interval, 1.00–22.3; p 
0.049); lymph node metastasis was also a significant prog-
nostic factor (relative risk, 5.81; 95% confidence interval,
1.94–17.4; p  0.002).
DISCUSSION
In the present study, we conducted a detailed analysis
of MUC1 expression in NSCLC, and classified NSCLC
patients into three groups according to MUC1 expression
patterns: such as high-grade polarized, low-grade polarized,
FIGURE 2. Postoperative survival of NSCLC patients ac-
cording to MUC1 expression pattern. HP, high-grade polar-
ized expression; LP, low-grade polarized expression; D, de-
polarized expression.
TABLE 2. Classification of MUC1 Expression Status
Classification of MUC1 Expression Status
HP LP D
Percentage of tumor cells showing polarized MUC1 expression 50% 50% Any
Percentage of tumor cells showing depolarized MUC1 expression 10% 10% 10% or more
TABLE 3. Characteristics of Patients and MUC1 Expression in Resected Lung Adenocarcinoma
No. of Patients (%) HP (%) LP (%) D (%) p Value
All patients 47 (100) 24 (51.1) 17 (36.2) 6 (12.8)
Mean age (yr) 63.5 66.6 65.2 0.596
65 27 (57.4) 12 (44.4) 11 (40.7) 4 (14.8) 0.571
65 20 (42.6) 12 (60.0) 6 (30.0) 2 (10.0)
Gender
Male 28 (59.6) 10 (35.7) 12 (42.9) 6 (21.4) 0.017
Female 19 (40.4) 14 (73.7) 5 (26.3) 0
Tumor differentiation
Well 28 (59.6) 21 (75.0) 7 (25.0) 0 0.0001
Moderate/poor 19 (40.4) 3 (15.8) 10 (52.6) 6 (31.6)
Pathologic stage
I 40 (85.1) 22 (55.0) 14 (35.0) 4 (10.0) 0.283
II/IIIA 7 (14.9) 2 (28.6) 3 (42.9) 2 (28.6)
Pathologic T factor
T1 29 (61.7) 16 (55.2) 11 (37.9) 2 (6.9) 0.308
T2/T3 18 (38.3) 8 (44.4) 6 (33.3) 4 (22.2)
Pathologic N factor
N0 40 (85.1) 22 (55.0) 14 (35.0) 4 (10.0) 0.283
N1/N2 7 (14.9) 2 (28.6) 3 (42.9) 2 (28.6)
HP, high-grade polarized expression; LP, low-grade polarized expression; D, depolarized expression.
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and depolarized expression. Some studies had already dem-
onstrated that enhanced depolarized MUC1 expression and
down-regulated MUC1 expression was positively correlated
with dedifferentiation of lung adenocarcinoma.36,37 In the
present study, HP expression was exclusively observed in
adenocarcinoma patients and was mostly observed in well-
differentiated adenocarcinoma patients; LP or D expression
was, in contrast, mostly observed in moderately to poorly
differentiated adenocarcinoma patients or in other histology
patients. These results are consistent with previous stud-
ies,36,37 and we propose the MUC1-expression classification
as a simple and effective method for evaluation of tumor
differentiation of lung adenocarcinoma.
We also assessed the prognostic significance of MUC1
expression pattern in resected NSCLC and showed that pa-
tients with depolarized MUC1 expression tended to show a
poor prognosis after thoracotomy for NSCLC; in lung ade-
nocarcinoma, depolarized expression proved to be a signifi-
cant factor for predicting a poor prognosis. The Kaplan-Meier
survival curves in the present study (Figures 2 and 3) showed
that postoperative death in D patients might occur in rela-
tively early phase of postoperative course as compared with
that in HP patients. Many clinical studies have demonstrated
that MUC1 status may be a useful marker of tumor progres-
sion and/or poor outcome in a variety of malignant tumors,
including thyroid,19 breast,20 gastric,21,22 pancreatic,23 bile
duct,24,25 gallbladder,26 ovarian,27 uterus endometrial,28 pros-
tate,29 and colorectal cancers30; results in the present study
that depolarized expression was a predictor of a poor prog-
nosis were inconsistent with these previous studies. In some
studies, aberrant MUC1 expression on the stroma-facing cell
surface (stromal pattern) or diffuse distribution in the cyto-
plasm (cytoplasmic pattern) was correlated with a poor prog-
nosis.25,26,30 In NSCLC, an expression pattern corresponding
to such stromal or cytoplasmic pattern has been described as
depolarized expression as defined in the present study, but
prognostic significance of MUC1 status has not been estab-
lished.6,31,32 Jarrard et al. proposed that MUC1 is a marker of
the type II pneumocyte lineage during carcinogenesis but
showed that MUC1 status, positive or negative, was not
correlated with survival.6 Guddo et al. classified MUC1
expression patterns into positive depolarized or negative
depolarized expression; positive depolarized MUC1 expres-
sion was correlated with poor survival in lung squamous cell
carcinoma patients, but not in adenocarcinoma patients.31
Tsutsumida et al. evaluated MUC1 expression in combination
with surfactant apoprotein A (SP-A) expression in small-size
lung adenocarcinoma; patients with tumors showing domi-
nant MUC1 expression over SP-A expression (MUC1 
SP-A) showed a significant poor survival, whereas MUC1
status alone was not correlated with survival.32 In the present
study, we conducted a more detailed MUC1 status classifi-
cation (HP, LP, and D), and showed a significant difference
in postoperative survival between HP and D patients in lung
adenocarcinoma.
Despite recent development of radiotherapy and che-
motherapy such as molecular targeting agents, the prognosis
of NSCLC patients with unresectable disease or postoperative
recurrence remains unsatisfactory.33 Now, immunotherapy
has been developed as a new option for cancer therapy.
MUC1 core protein may be a useful target molecule for
immunotherapy in breast cancer and other malignancies ex-
pressing MUC1 including NSCLC.18,38,39 Because antitumor
effecter cells such as cytotoxic T lymphocytes may infiltrate
into tumor parenchyma from stromal vessels around tumor,40
a MUC1-targeted immunotherapy may be more appropriate
for tumors showing depolarized MUC1 expression than those
showing polarized expression on the ductal side of tumor
cells. Correlation between the efficacy of a MUC1-targeted
immunotherapy and MUC1-expression status should be in-
vestigated.
In conclusion, we proposed a novel classification of
MUC1 expression pattern and showed that the classification
was a useful marker correlated with postoperative survival as
well as tumor differentiation in lung adenocarcinoma.
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